title: Cost-effectiveness modelling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in Finland.
abstract: OBJECTIVE
  The main objective was to compare the cost-effectiveness of therapeutic options in moderate or severe rheumatoid arthritis (RA) when a clinical response to a first TNF-blocker, either etanercept (ETA), adalimumab (ADA), or infliximab (INF), is insufficient.
  
  
  METHODS
  Effectiveness criteria were defined as remission (RS), low disease activity (LDAS), and moderate to high disease activity (MHDAS). Cost-effectiveness was derived as cost per day in RS and in LDAS using simulation modelling to assess six sequential biologic strategies over 2 years. Each sequential treatment strategy was composed of three biologic agents and included a first anti-TNF agent, ETA, ADA or INF, followed by either abatacept (ABA) or rituximab (RTX) as a second therapeutic option in case of an insufficient response, followed by another anti-TNF agent in case of further insufficient response.
  
  
  RESULTS
  Over two years and taking into account biologic costs, the following estimated mean costs per day in RS and LDAS were respectively of €829 and €428 for the biologic sequence composed of ADA-ABA-ETA, €1292 and €516 for the sequence ADA-RTX-ETA, €829 and €429 for the sequence ETA-ABA-ADA, €1292 and €517 for the sequence ETARTX- ADA, €840 and €434 for the sequence INF-ABA-ETA, and €1309 and €523 for the sequence INF-RTX-ETA.
  
  
  CONCLUSIONS
  The treatment sequences including ABA as the second biologic option appear more cost-effective than those including RTX in a patients with moderate to severe RA and an insufficient response to a first anti-TNF agent.
authors.affiliation: Lappeenranta Central Hospital, Lappeenranta, Finland.
authors.forename: K
authors.initials: K
authors.lastname: Puolakka
authors.forename: H
authors.initials: H
authors.lastname: Blåfield
authors.forename: M
authors.initials: M
authors.lastname: Kauppi
authors.forename: R
authors.initials: R
authors.lastname: Luosujärvi
authors.forename: R
authors.initials: R
authors.lastname: Peltomaa
authors.forename: T
authors.initials: T
authors.lastname: Leikola-Pelho
authors.forename: K
authors.initials: K
authors.lastname: Sennfalt
authors.forename: A
authors.initials: A
authors.lastname: Beresniak